Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma.
Adult
Aged
Chemoradiotherapy
/ adverse effects
Deglutition
Deglutition Disorders
/ diagnostic imaging
Female
Fluoroscopy
/ methods
Follow-Up Studies
Humans
Hypoglossal Nerve
/ radiation effects
Male
Middle Aged
Organs at Risk
/ radiation effects
Oropharyngeal Neoplasms
/ mortality
Pharyngeal Muscles
/ radiation effects
Radiation Dosage
Radiation Injuries
/ complications
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ mortality
Time Factors
Tongue
/ radiation effects
Tongue Neoplasms
/ therapy
Chemoradiation
Dysphagia
Head and neck cancer
Late toxicity
Oropharyngeal cancer
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
21
04
2020
revised:
03
06
2020
accepted:
07
06
2020
pubmed:
18
8
2020
medline:
14
9
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Improved prognosis for p16+ oropharyngeal squamous cell carcinoma (OPSCC) has led to efforts to mitigate long-term complications of treatment, which remains poorly defined in late survivors. Here we characterize very late dysphagia in OPSCC. Long-term review of 93 p16+ OPSCC patients treated with chemoradiation was performed. We scored videofluoroscopic swallow studies (VFSS) according to the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale. Very late dysphagia was defined >2.5 years from end of treatment. Fine-Gray regression models were used to assess dysphagia with competing risk of death. Median follow up was 10.5 years. 402 total VFSS were assessed (median 4 per patient, range 0-8). 15.1% of patients had a DIGEST score ≥2 very late after treatment. Very late DIGEST score ≥2 correlated with T-stage (HR 1.7, p = 0.049), second cancer (HR 6.5, p = 0.004), superior pharyngeal constrictor dose (HR 1.11, p = 0.050), total tongue dose (HR 1.07, p = 0.045), but not hypoglossal nerve dose (p > 0.2). Seven patients (7.5%) had late progressive dysphagia, defined as DIGEST score that increased by ≥2 beyond one year after treatment, and this correlated with higher ipsilateral hypoglossal nerve D1cc dose (75 vs 72 Gy, p = 0.037). In p16+ OPSCC patients treated with definitive chemoradiation, at least 7.5% developed late progressive dysphagia, and 15.1% experienced moderate dysphagia >2.5 years from treatment. Our study suggests that dose to tongue musculature may be associated with very late dysphagia, and hypoglossal nerve dose may be associated with late progressive dysphagia. More intensive long-term dysphagia survivorship monitoring is suggested.
Identifiants
pubmed: 32805634
pii: S1368-8375(20)30289-X
doi: 10.1016/j.oraloncology.2020.104853
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
104853Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.